Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face.

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.